FDA grants De Novo authorization to Vitestro Aletta, first standalone robotic blood draw device
[REGULATORY ACTION]Aug 19, 2026 · Investigated by FDA · Vitestro
Failure Mode
REGULATORY ACTION
Event Date
Aug 19, 2026
Primary Entity
Investigated by FDA
Robotic Platform
Vitestro
Jurisdiction / Location
Federal / Global
Audit Standard
Physical State Verified
Incident Abstract & Audit Findings
The FDA granted De Novo classification to Vitestro Aletta, the first standalone robotic device that can draw blood from a patient arm without hands-on operator intervention. Clinical data showed Aletta achieves successful blood draw rates comparable to or better than trained human phlebotomists across a broad range of patients. The device includes onboard sensors that can pause the procedure and alert a supervising phlebotomist if unsafe conditions are detected.
System & Fleet Architecture
Operating Manufacturer
Hardware Platform
Operational Sectors
Primary Sources & Evidentiary Filings
- Inspect Filing
https://www.fda.gov/news-events/press-announcements/fda-authorizes-first-its-kind-robotic-blood-draw-device
https://www.fda.gov/news-events/press-announcements/fda-authorizes-first-its-kind-robotic-blood-draw-device
Related Incidents & Failure Precedents
6 records on file- NHTSA opens probe into 1.2 million Tesla Model 3 and Model Y vehicles over front suspension failures[REGULATORY ACTION]
Jul 31, 2026 · Tesla · Tesla Robotaxi (Model Y ADS) · Orlando, Florida, USA
Details - NHTSA grants Zoox temporary exemption to commercially deploy up to 2,500 robotaxis annually[REGULATORY ACTION]
Jul 30, 2026 · Zoox · Zoox Robotaxi · Miami
Details - Zoox clears final federal hurdle, receives NHTSA exemption to launch paid robotaxi service[REGULATORY ACTION]
Jul 30, 2026 · Zoox · Zoox Robotaxi · Miami
Details - NHTSA grants Zoox first-ever commercial FMVSS exemption for purpose-built robotaxi[REGULATORY ACTION]
Jul 30, 2026 · Zoox · Zoox Robotaxi · Miami
Details - NHTSA launches $5M SAE ITC partnership to develop first-ever AV performance standards and updates AV technical guidance[REGULATORY ACTION]
Jul 30, 2026 · Zoox · Zoox Robotaxi · Miami
Details - NHTSA grants Zoox temporary commercial deployment exemption for up to 2,500 robotaxis annually for two years[REGULATORY ACTION]
Jul 30, 2026 · Zoox · Zoox Robotaxi · Miami
Details
Incident Context & FAQ
What happened in FDA grants De Novo authorization to Vitestro Aletta, first standalone robotic blood draw device?
The FDA granted De Novo classification to Vitestro Aletta, the first standalone robotic device that can draw blood from a patient arm without hands-on operator intervention. Clinical data showed Aletta achieves successful blood draw rates comparable to or better than trained human phlebotomists across a broad range of patients. The device includes onboard sensors that can pause the procedure and alert a supervising phlebotomist if unsafe conditions are detected.
When did this incident occur?
The incident is recorded as occurring on August 19, 2026 on the DEPLOY registry. The date reflects the underlying real-world event, not the registry record's creation date.
Who was involved in FDA grants De Novo authorization to Vitestro Aletta, first standalone robotic blood draw device?
The incident is recorded as involving Vitestro on the DEPLOY registry. No specific robot model is linked to this incident in the registry.
Has anyone responded to FDA grants De Novo authorization to Vitestro Aletta, first standalone robotic blood draw device?
No responses to this incident are recorded on the DEPLOY registry. Operators, manufacturers, or affected parties can submit responses to the editorial team; absence is not a guarantee no response was issued.
What is the current status of FDA grants De Novo authorization to Vitestro Aletta, first standalone robotic blood draw device?
This incident is an active record on the DEPLOY registry; no retraction or correction has been issued.